Bristol-Meyers Squibb Acquires Cardioxyl Pharmaceuticals for $2,075,000,000
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=50a03547-6f0e-4609-bb65-0f58781fdcaf - Date
11/2/2015 - Company Name
Cardioxyl Pharmaceuticals - Mailing Address
1450 Raleigh Road Chapel Hill, NC 27517 USA - Company Description
Cardioxyl Pharmaceuticals’ mission is the discovery and development of newclasses of safe and effective therapeutic agents for the treatment ofcardiovascular disease. Cardioxyl’s initial program is a novel medication forthe treatment of acute decompensated heart failure. - Website
http://www.cardioxyl.com - Transaction Type
M&A - Transaction Amount
$2,075,000,000 - Transaction Round
- Proceeds Purposes
- M&A Terms
The transaction includes upfront and near-term milestone payments of up to $300 million and potential additional consideration of up to $1.775 billion upon the achievement of certain development, regulatory and sales milestones.
